Gareth Morgan Investments Limited Partnership cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 86.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,573 shares of the company’s stock after selling 95,391 shares during the quarter. Gareth Morgan Investments Limited Partnership’s holdings in Johnson & Johnson were worth $1,940,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Lau Associates LLC boosted its holdings in Johnson & Johnson by 12.8% during the 1st quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after acquiring an additional 5,335 shares during the period. Jackson Grant Investment Advisers Inc. boosted its holdings in Johnson & Johnson by 7.3% during the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock valued at $1,627,000 after acquiring an additional 957 shares during the period. Burke & Herbert Bank & Trust Co. boosted its holdings in Johnson & Johnson by 2.6% during the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock valued at $5,895,000 after acquiring an additional 1,218 shares during the period. Paradigm Financial Advisors LLC boosted its holdings in Johnson & Johnson by 17.1% during the 1st quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock valued at $328,000 after acquiring an additional 386 shares during the period. Finally, Peachtree Investment Advisors Inc. boosted its holdings in Johnson & Johnson by 0.7% during the 1st quarter. Peachtree Investment Advisors Inc. now owns 22,138 shares of the company’s stock valued at $2,757,000 after acquiring an additional 160 shares during the period. Institutional investors own 66.00% of the company’s stock.
Johnson & Johnson (JNJ) traded down 0.86% on Tuesday, reaching $132.06. The company had a trading volume of 2,401,178 shares. The company has a market capitalization of $354.45 billion, a P/E ratio of 22.35 and a beta of 0.79. The stock’s 50-day moving average is $132.39 and its 200-day moving average is $128.93. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.74 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/09/12/gareth-morgan-investments-limited-partnership-has-1-94-million-position-in-johnson-johnson-jnj.html.
JNJ has been the subject of several analyst reports. Morgan Stanley increased their target price on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Cowen and Company set a $147.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. UBS AG reiterated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price objective on shares of Johnson & Johnson in a report on Friday, June 16th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $134.60.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.